secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0000950170-25-065618
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines Q1 net loss $213.4M; highlights encouraging RAS inhibitor data
--------------------------------------------------------------------------------

- Net loss $213.4M (vs $116.0M YoY); R&D $205.7M, G&A $35.0M; cash $2.1B.
- FY 2025 GAAP net loss guidance reaffirmed $840M-$900M; cash runway into H2 2027.
- Daraxonrasib Phase 3 PDAC trial enrollment to substantially complete in 2025; data in 2026.
- Zoldonrasib G12D NSCLC ORR 61%; elironrasib G12C NSCLC ORR 56%, median PFS 9.9 mo.
- Anthony Mancini named chief global commercialization officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000095017025065618/0000950170-25-065618-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000095017025065618/rvmd-20250507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-065618

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer